In collaboration with Emory University, we follow more than 1,000 children and adults with bleeding disorders and approximately 200 with clotting disorders in our Comprehensive Hemostasis and Thrombosis Program. We treat a wide range of disorders, including hemophilia, thrombosis and von Willebrand disease.
Our program:
- Is a recognized leader among treatment facilities in the U.S. for achievements in care, education and research for patients with congenital bleeding disorders.
- Has developed a successful, integrated pediatric- and adult-care model that reduces the stress and barriers associated with transitions from a pediatric to an adult-care facility for patients with bleeding disorders.
- Participates in innovative clinical, epidemiological, translational and basic science research designed to provide leading-edge therapies and eventual cures.
- Was recently awarded a grant to be the national private for ATHN 9 American Thrombosis and Hemostasis Network Study entitled “A Real-World Safety and Efficacy Study of Prophylaxis for Severe von Willebrand Disease.”
- Is completing an NHLBI U54 award entitled “Translational Research Centers in Thrombotic and Hemostatic Disorders,” and was recently selected as one of four NHLBI-funded Centers for the Investigation of Factor VIII Immunogenicity.
- Team investigators were selected as one of three national NHLBI U54 Centers for the Investigation of the Factor VIII Immune Response in Patients with Hemophilia A. The U54 grant is a five-year award that will expire in 2023.
Click the link for more information about our Hemostasis/Thrombosis Program and research.
Our hemostasis and thrombosis team:
- Glaivy Batsuli, MD
- Carolyn Bennett, MD, MSc
- Renhao Li, PhD
- John (Pete) Lollar III, MD
- Shannon Meeks, MD, Program Medical Director
- Seema Patel, PhD
- Robert Sidonio Jr., MD, MSc, Medical Director Hemophilia
- Yingchun Wang, MD, PhD
- Michael White, MD
- Gary Woods, MD, Medical Director Thrombosis
- Karen Zimowski, MD